However, tumours with a high HER2 expression (clinically HER2-positive tumours) can be successfully treated using a targeted therapy with a monoclonal antibody trastuzumab, an antibody–drug conjugate trastuzumab–emtansine or a combination of the antibodies trastuzumab and pertuzumab [2,3]. Here, ERBB2 is linked to neoplasm.